The drive towards newer Java versions and updated enterprise specifications isn’t just about keeping up with the latest tech; ...
I'm a Fitness & Nutrition writer for CNET who enjoys reviewing the latest fitness gadgets, testing out activewear and sneakers, as well as debunking wellness/fitness myths. In my free time I enjoy ...
Amgen has terminated its rocatinlimab collaboration with Kyowa Kirin, walking away from the anti-OX40 antibody five years after paying $400 million for rights to the autoimmune disease drug candidate.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results